Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00800540 · ClinicalTrials.gov registry record · Phase 4
Circadian Ocular Perfusion Pressure and Ocular Blood Flow
A Phase 4 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
NCT00800540: Completed Phase 4 study, sponsored by Alcon Research.
NCT00800540 is a Phase 4 study that has completed, run by Alcon Research. The registered enrollment target is 35 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00800540, a Phase 4 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this study was to compare the short term effects of two intraocular pressure (IOP) lowering medications on ocular perfusion pressure (OPP), ocular blood flow, intraocular pressure, and blood pressure in patients with glaucoma. Ocular perfusion pressure (OPP) is defined as the difference between arterial blood pressure (diastolic and systolic) and intraocular pressure. The primary efficacy assessment is based on diastolic ocular perfusion pressure.
Primary Outcome
Diastolic ocular perfusion pressure (DOPP) is defined as the difference between diastolic arterial pressure and intraocular pressure. Diastolic arterial pressure was measured with a calibrated automated sphygmomanometer. Intraocular pressure was measured with a calibrated pneumatonometer. A lower DOPP indicates a lower optic blood supply, which can be a risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).
Interventions
- DRUG Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension
- DRUG Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2009-02 |
| Est. Completion | 2012-01 |
| Phase | Phase 4 |
What the finished NCT00800540 record still lists
NCT00800540 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension is the first listed.
NCT00800540 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00800540 about?
NCT00800540 is a clinical study titled "Circadian Ocular Perfusion Pressure and Ocular Blood Flow". The purpose of this study was to compare the short term effects of two intraocular pressure (IOP) lowering medications on ocular perfusion pressure (OPP), ocular blood flow, intraocular pressure, and blood pressure in patients with glaucoma. Ocular perfusion pressure (OPP) is defined as the differen...
What is the current status of trial NCT00800540?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2009-02. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00800540?
The interventions under investigation include: Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension (DRUG), Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution (DRUG).
Who is sponsoring clinical trial NCT00800540?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00800540's enrollment target sits among peer trials
35 1506th of 2000 higher than 481 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia